347166-09-0

Upstream product

• 503859-29-8 2-(4-benzyloxy-phenyl)-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid methyl ester 
• 87815-77-8 4-cyclohexylamino-3-nitrobenzoic acid ethyl ester 
• 347174-05-4 3-Amino-4-cyclohexylamino benzoic acid ethyl ester 
• 367-80-6 ethyl 4-fluoro-3-nitrobenzoate 
• 1486-51-7 p-(benzyloxy)benzoic acid 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 1486-50-6 4-(benzyloxy)benzoic acid chloride 
• 885312-82-3 2-(4-benzyloxy-phenyl)-1-cyclohexyl-1H-benzoimidazole-5-carboxylic acid ethyl ester 

Downstream Products

• 503857-60-1 N-({2-[4-(Benzyloxy)phenyl]-1-cyclohexyl-1H-benzimidazol-5-yl}carbonyl)methanesulfonamide 

Relevant academic research and scientific papers

Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: Identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole

A series of 1-cycloalkyl-2-phenyl-1H-benzimidazole-5-carboxylic acid derivatives was synthesized and evaluated for inhibitory activity against HCV NS5B RNA-dependent RNA polymerase (RdRp). A SAR study was performed and led to identify the 2-[(4-diarylmeth

NITROGEN-CONTAINING HETEROARYL DERIVATIVES

Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

Compounds useful for treating hepatitis C virus

A series of compounds of Formula I are disclosed which are useful in treating viral hepatitus C. 1

Fused-ring compounds and use thereof as drugs

The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. Th